Then taking advantage of the complexation between CD44 and HA, the obtained HA/PLL NPs can selectively bound CD44 in vitro with good targeting property, and can diminish cancer cell migration in a receptor-selective manner and co-localized with CD44 receptor in vivo, as demonstrated by the bioimaging photos in Figure 5(c). The gene discussed is CD44; the disease is cancer.